Saturday, August 22, 2026
ExploreSearch
Via News
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Platforms Rush to Establish Content-Authenticity Standards Amid Leadership Shakeups and Sustained Capex
Within days of each other in mid-August 2026, Google, Anthropic, and Spotify moved to formalize AI content watermarking and labeling policies, signaling an industry-wide push toward self-governed provenance standards as generative AI output floods consumer platforms. The shift coincides with executive turnover at OpenAI (Brad Lightcap's departure) and Meta's public AI manifesto, all set against continued heavy AI infrastructure capital expenditure and finance-sector moves (e.g., Wall Street paying for algorithmic edges on social signals) that underscore AI's deepening entanglement with capital markets.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts report JPMorgan Chase & Co.'s revenue for the same fiscal period (FY 2025) with the same observation date (2025-12-31), but with different values: $182.447 billion vs. $185 billion. The ~1.4% difference ($2.553 billion) is too large to be explained by rounding alone and represents conflicting data for the identical time period.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,977
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,977 facts checked against source5,242 source documents archived
Work with this data → vianewsagency.com
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· February 13, 2026

Moderna Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Updates

View original at finance.yahoo.com
Moderna Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Updates Reports fourth quarter revenue of $0.7 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.11) Reports full-year revenue of $1.9 billion, GAAP net loss of $(2.8) billion and GAAP diluted EPS of $(7.26) Reiterate…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • 2026 SG&A expenses projected to be approximately $1.0 billion

    80% confidence

  • Moderna expects potential propionic acidemia therapeutic data readout in 2026

    80% confidence

  • Moderna is poised to deliver up to 10 percent revenue growth through mNEXSPIKE expansion and international strategic partnerships

    80% confidence

  • Intismeran autogene in combination with KEYTRUDA reduced the risk of recurrence or death by 49% compared to KEYTRUDA alone in five-year Phase 2b adjuvant melanoma data

    80% confidence

  • 2026 revenue targeting up to 10% growth from 2025 with approximately 50% U.S. and 50% international split

    80% confidence

  • Moderna expects potential Phase 2 mRNA-4359 data readout in 2026

    80% confidence

  • In 2025, Moderna sharpened commercial execution, launched third product and brought online three international manufacturing sites, while advancing mRNA pipeline and lowering annual operating expenses by approximately $2.2 billion

    80% confidence

  • Seasonal vaccines expected to deliver up to 10% revenue growth in 2026

    80% confidence

  • Moderna expects potential Phase 3 adjuvant melanoma data in 2026

    80% confidence

  • 2026 cost of sales expected to be approximately $0.9 billion

    80% confidence

  • Moderna looks forward to delivering multiple potential product approvals and late-stage clinical readouts, while driving continued innovation across mRNA platform

    80% confidence

  • Year-end 2026 cash and investments projected to be $5.5 to $6.0 billion, excluding any additional credit facility drawdown

    80% confidence

  • 2026 R&D expenses anticipated to be approximately $3.0 billion

    80% confidence

Cited in these Via News reports